Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...

Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

The trial was tiny, just 16 patients, but it’s eliciting a sentiment not normally associated with this brutal disease of ...

An Indian origin scientist Vinod Balachandran, MD, in latest data from the phase 1 trial has revealed that an investigational ...

The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

For pancreatic NETs, you might have one of the following ... It helps to make your immune system find and kill cancer cells. It is a type of immunotherapy for some types of lung neuroendocrine ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...